...
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Therapeutic polyclonal human CD8 + CD25 + Fox3 + TNFR2+ PD-L1 + regulatory cells induced ex-vwo
【24h】

Therapeutic polyclonal human CD8 + CD25 + Fox3 + TNFR2+ PD-L1 + regulatory cells induced ex-vwo

机译:多克隆人CD8 + CD25 + Fox3 + TNFR2 + PD-L1 +治疗性细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract We report that polyclonal CD8regs generated in one week ex-vivo with anti-CD3/28 beads and cytokines rapidly developed suppressive activity in vitro sustained by TGF-beta.. In im-munodeficient mice, these CD8regs demonstrated a markedly protective, IL-10 dependent activity against a xeno-GVHD. They expressed IL-2Ralpha/beta, Foxp3, TNFR2, and the negative co-stimulatory receptors CTLA-4, PD-1, PD-L1 and Tim-3. Suppressive activity in vitro correlated better with TNFR2 and PD-L1 than Foxp3. Blocking studies suggested that TNF enhanced PD-L1 expression and the suppressive activity of the CD8regs generated. Unlike other polyclonal CD4 and CD8 Tregs, these CD8regs preferentially targeted allogeneic T cells, but they lacked cytotoxic activity against them even after sensitization. Unlike CD4regs, these CD8regs could produce IL-2 and proliferate while inhibiting target cells. If these CD8regs can persist in foreign hosts without impairing immune surveillance, they could serve as a practical remission-inducing product for the treatment of autoimmune diseases, graft-versus-host disease, and allograft rejection.
机译:摘要我们报告说,在离体一周内与抗CD3 / 28珠和细胞因子一起产生的多克隆CD8regs在体外由TGF-β迅速产生了抑制活性。在免疫缺陷小鼠中,这些CD8regs具有明显的保护性IL-针对异种GVHD的10种依赖性活性。他们表达了IL-2Ralpha / beta,Foxp3,TNFR2,以及负共刺激受体CTLA-4,PD-1,PD-L1和Tim-3。与Foxp3相比,体外抑制活性与TNFR2和PD-L1的相关性更好。阻断研究表明,TNF增强了PD-L1的表达并抑制了所产生的CD8regs的活性。与其他多克隆CD4和CD8 Treg不同,这些CD8reg优先靶向同种异体T细胞,但即使在敏化后,它们也缺乏针对它们的细胞毒活性。与CD4regs不同,这些CD8regs可以产生IL-2并在抑制靶细胞的同时增殖。如果这些CD8regs可以在异源宿主中持续存在而又不影响免疫监视,则它们可以作为治疗自身免疫性疾病,移植物抗宿主病和同种异体移植排斥反应的实用诱导物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号